Physician profile
Benjamin Deaton
NPI 1376803437
$2,259.27
in general payments reported to CMS, 2019-2025
27 companies · $1,060 in 2025
The $1,060 reported for 2025 was more than what 78% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $137 · 2023: $288 · 2024: $775 · 2025: $1,060.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,122.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,122.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $482.42 | 2024-2025 | |
| Abiomed | $326.22 | 2023-2025 | Impella |
| Grifols USA, LLC | $181.70 | 2023-2025 | Prolastin-C Liquid |
| Astrazeneca Pharmaceuticals Lp | $159.01 | 2024-2025 | Breztri, Tezspire, Fasenra |
| Nuwellis, INC. | $136.88 | 2022 | |
| Baxter Healthcare | $106.33 | 2023-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| Merck Sharp & Dohme LLC | $81.18 | 2024-2025 | Zerbaxa, Recarbrio |
| Actelion Pharmaceuticals US, INC. | $76.45 | 2023-2025 | Uptravi, Opsumit |
| Janssen Pharmaceuticals, INC | $73.79 | 2024 | Xarelto |
| Coaptech, INC. | $66.35 | 2024-2025 | Puma System, Puma System |
| Electromed, INC. | $65.16 | 2024-2025 | Smartvest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.63 | 2023-2024 | Ofev |
| Viatris Specialty LLC | $49.63 | 2025 | Yupelri |
| United Therapeutics Corporation | $42.54 | 2023-2024 | Tyvaso |
| Verona Pharma, INC. | $41.88 | 2025 | Ohtuvayre |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $40.59 | 2024 | Briviact |
| Shionogi INC | $37.28 | 2024 | Fetroja |
| Medtronic, INC. | $30.84 | 2025 | Vitalflow Console |
| Ani Pharmaceuticals, INC. | $29.71 | 2025 | Purified Cortrophin Gel |
| Regeneron Healthcare Solutions, INC. | $26.89 | 2023 | Dupixent |
| Vifor Pharma, INC. | $26.64 | 2024 | Veltassa |
| Insmed, INC. | $23.25 | 2024 | Arikayce |
| La Jolla Pharmaceutical Company | $22.30 | 2024 | Giapreza |
| Mylan Specialty L.P. | $21.93 | 2024 | Yupelri |
| Glaxosmithkline, LLC. | $19.50 | 2023 | Trelegy Ellipta |
| Pfizer INC. | $18.33 | 2025 | |
| Liquidia Technologies, INC. | $17.84 | 2025 | Yutrepia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Deaton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.